Growing prevalence of bacterial infections is expected to drive the growth of India gentamycin market.
According to TechSci Research report, “India Gentamycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Eye Drops, Tablet, Capsule, Syrup, Injection, Cream, Gel, Ointment, Others), By Route of Administration (Ophthalmic, Intravenous, Topical, Oral, Others), By Distribution Channel (Online v/s Offline), By Application (Bacterial Infection, Urinary Tract Infection, Sepsis, Meningitis, Skin or Soft Tissue Infection, Upper Respiratory Tract Infection, Others), By Company, By Region, Forecast & Opportunities, FY2026”, the India gentamycin market is expected to grow at a steady rate during the forecast period on account of the widespread use of the drug in treatment of meningitis, cystic fibrosis, pelvic respiratory diseases, plague, pneumonia, conjunctivitis, among others.
Additionally, availability in different forms ranging from capsules, tablet, syrup, gel, ointments, among others are further expected to fuel the market growth through FY2026. Furthermore, the drug is even used as second line of treatment against bacteria having resistance towards any particular antibiotic. This in turn is expected to propel the market growth over the next few years. Also, the drug is present in the WHO’s list of essential medicine, thereby increasing the demand for the antibiotics and fostering the market growth during the forecast period. However, inner ear problems and kidney problems are the most commonly observed side effects observed due to consumption of gentamycin. This in turn is expected to restrict the market growth over the next five years.
Browse XX market data Tables and XX Figures spread through XX Pages and an in-depth TOC on“ India Gentamycin Market “
https://www.techsciresearch.com/report/india-gentamycin-market/5167.html
The India gentamycin market is segmented based on source, form, route of administration, distribution channel, application, company and region. Based on source, the market can be split into in-house and contract manufacturing organizations. The contract manufacturing organizations segment is expected to register significant growth in the market through FY2026. This can be ascribed to the fact that various pharmaceutical companies have started outsourcing the production of several drugs and APIs to these organizations so that they can focus on research and development of new drugs and their expansion.
Additionally, these organizations have the capability of manufacturing even large quantities of the formulations depending upon the client requirement in a shorter duration of time and at a very competitive price. Based on form, the market can be categorized into eye drops, tablet, capsule, syrup, injection, cream, gel, ointment and others. The tablet segment is expected to dominate the market since it can accommodate a large amount of API as compared to the other counterparts. While capsule segment is expected to register the highest growth during the forecast period on account of the associated benefits such as fast action, tamper resistance, higher rate of absorption, among others.
Based on distribution channel, the market can be split into online and offline. The offline channel is expected to dominate the market owing to the consumer preference for buying medicines from a pharmacy or drug store. The online segment is also expected to register significant growth over the next few years. This can be ascribed to the emergence of several online pharmacies, digital platforms and doorstep drug delivery e-commerce platforms in the country.
Taj Pharmaceuticals Ltd., Bayer India Ltd., Zydus Cadila Healthcare Ltd., Neon Laboratories Ltd., Hetero Healthcare Ltd., Gracure Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Fresenius Kabi India Pvt. Ltd., Nestor Pharmaceuticals Ltd. and others are some of the leading players operating in India gentamycin market. Companies operating in the market are using organic strategies such as product launches, mergers and collaborations to boost their share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5167
Customers can also request for 10% free customization on this report.
“India gentamycin market is expected to witness growth during the forecast period on account of the growing prevalence of diabetes in the country. India is the country with second highest diabetic population in the world and gentamycin is also being used as an anti-diabetic drug thereby driving the market growth. Additionally, the widespread use of the antibiotic for treatment of a wide range of bacterial infections is further expected to spur the market growth through FY2026.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“India Gentamycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Eye Drops, Tablet, Capsule, Syrup, Injection, Cream, Gel, Ointment, Others), By Route of Administration (Ophthalmic, Intravenous, Topical, Oral, Others), By Distribution Channel (Online v/s Offline), By Application (Bacterial Infection, Urinary Tract Infection, Sepsis, Meningitis, Skin or Soft Tissue Infection, Upper Respiratory Tract Infection, Others), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India gentamycin market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India gentamycin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]